Introduction {#S1}
============

The lymphatic system is comprised of highly permeable capillaries found within the tissue and are required to transport lymph which contains cellular proteins, lipoproteins and lymphocytes ([@B22]; [@B49]; [@B71]; [@B37]; [@B84]; [@B76]). The capillaries drain into collecting lymphatic vessels (LV) surrounded by lymphatic muscle cells (LMC) that pump the lymph through highly specialized lymphatic valves ([@B14]). How or if liver disease changes the normal functions of the lymphatics in the liver is not well understood. Here, we will outline current knowledge regarding the liver lymphatic system and lymphatic dysfunction in other organs to highlight underlying questions of how lymphatics may be affected by chronic liver disease (CLD).

Liver Lymphatics in Health {#S2}
==========================

The liver is the largest contributor to lymph production in the body and accounts for up to 50% of lymph entering the thoracic duct ([@B82]). This lymph originates predominantly from the blood vascular system, which is characterized by a portal vein (PV) and hepatic artery (HA) in the portal triad spanning the hepatic lobule to the central vein (CV). Lymphatic structures are found within the portal triad near the PV and bile duct ([Figure 1](#F1){ref-type="fig"}). These are likely lymphatic capillaries (LC) with highly permeable button like junctions and are not surrounded by smooth muscle actin ([@B81]). Fluid from the blood vasculature leaks into the interstitium through highly permeable liver sinusoidal endothelial cells (LSEC). These highly permeable sinusoids are thought to lead to the higher protein content of hepatic lymph as compared to lymph in other organs ([@B17]; [@B93]; [@B5]). Cellular byproducts from hepatocytes, hepatic stellate cells (HSCs) and Kupffer cells also flow into the interstitium.

![Graphical illustration of liver blood and lymph circulation. Blood (purple arrows) flows into the portal vein (PV) from the gastrointestinal tract (GI) or into hepatic artery (HA) from the aorta. PV and HA as depicted in this figure are branches of the PV and HA. The blood is then transported through the liver sinusoids (red arrows) made up of liver sinusoidal endothelial cells (LSEC) and exits the liver through the central vein (CV) where it returns to circulation via the hepatic vein (HV). The primary source of lymph (blue arrows) travels from the sinusoids, through the Space of Disse, where it enters the Space of Mall and then enters the lymphatic capillaries (LC). The LC are made up of highly permeable button-like junctions that allow cells and protein to easily pass through. Upon entry into the lymphatic capillary the fluid and cells are then propelled through the lymphatic vessels (LV) where lymphatic muscle cells (LMC) pump the lymph toward the draining lymph node (LN). The lymphatic vessels contain valves for unidirectional flow. More than 80% of lymph is transported to portal lymphatic vessels. Superficial and sublobular lymph flow are not shown here.](fphys-10-01579-g001){#F1}

From the interstitium of the liver, fluid flows into the space of Disse located between the hepatocytes and the blood sinusoids of the liver. The lymphatic fluid then predominantly flows through the space of Mall at the interface of the portal tract and the adjacent hepatocytes. Eighty percent or more of the lymph then flows into LC found along the portal tract ([@B73]) with lymph flow in the same direction as bile and prevented from re-entering the liver by lymphatic valves in downstream collecting vessels ([@B87]). The LC then drain into LV which are surrounded by lymphatic muscle cells (LMC). These LMCs are needed to pump the lymph from the liver into the portal and the celiac lymph nodes (LNs) in mice ([@B8]; [@B102]; [@B14]; [Figure 1](#F1){ref-type="fig"}). The portal and celiac LNs in mice correlate to analogous hepatic draining LN clusters in humans ([@B38]), from which lymph drains into the cisterna chyli.

In addition to portal lymph there is also sublobular and superficial lymph. Sublobular LV are found along the inferior vena cava ([@B62]). Superficial lymph drains through various LC toward the periphery of the liver before entering LV draining to regional LNs ([@B72]). These studies describing the normal flow and function of the lymphatics in the liver lay the groundwork for understanding how lymphatic function in the liver could be compromised during disease.

Liver Lymphatics in Disease {#S3}
===========================

During inflammation, lymphangiogenesis occurs in response to vascular endothelial growth factors (VEGF) expressed by infiltrating macrophages ([@B44]). While the precise cell types that produce VEGFC/D to induce lymphangiogenesis in the liver are unknown, several liver resident cells including Kupffer Cells and LSECs have been shown to produce VEGFC/D ([@B21]; [@B56]). During end-stage liver disease such as Hepatitis C Viral infection (HCV), Hepatitis B viral infection (HBV), Non-Alcoholic Steatohepatitis (NASH), and Alcoholic Liver Disease (ALD), hepatic lymph production and lymphatic vessel frequency increases in both human patients and animal models ([@B63]; [@B98]; [@B99]; [@B81]). This same phenomenon of increased lymphatic vessel density, especially in the periportal area, has also been observed in idiopathic portal hypertension and in primary biliary cirrhosis ([@B63]; [@B97]). The increase in lymphatic vessel density correlates with documented increases in VEGFC/D in the cirrhotic liver ([@B88]). In patients with cirrhosis there is also an increase in the volume of lymph fluid draining the liver ([@B25], [@B26]; [@B92]; [@B34]). However, several studies have reported that the lymph fluid released from the liver, normally rich in protein, has a low protein content in humans ([@B94]; [@B95]) and rats ([@B9]) with cirrhosis. These findings suggest that despite the increase in frequency of lymphatics during disease, there may be a decrease in lymphatic permeability which prevents the proper removal of inflammatory mediators and cells from the liver. Despite these findings, it has yet to be determined if the lymphatics in the liver are functioning properly or if these changes in lymph content occur as a consequence of other disease-dependent mechanisms.

Liver Lymphatic Endothelial Cells {#S4}
=================================

The network of liver LV develops in the prenatal period ([@B68]) by differentiation from blood vasculature through the expression of *Prox1* ([@B90]). *Prox1*, the transcription factor required for lineage commitment of lymphatic endothelial cells (LEC) ([@B91]; [@B69]), is also expressed by hepatocytes ([@B24], [@B23]; [@B81]). As such, the lymphatic vasculature in the liver lacks a single specific marker, however, LV can specifically be imaged using PDPN (D2-40) in humans. The D2-40 stain in humans is fairly specific for lymphatic vasculature and not the vascular endothelium nor liver epithelium ([@B99]; [@B81]). However, this is not as straight forward in mice as cholangiocytes are positive for the 8.1.1 anti-mouse PDPN clone ([@B29]). Other common lymphatic endothelial markers include LYVE-1, but in the liver LYVE-1 is also expressed on LSECs and macrophages ([@B58]). VEGFR3, which is an essential tyrosine kinase receptor in vascular endothelial growth, is also expressed by other cells in the liver including LSECs and cholangiocytes ([@B32]; [@B81]). Other less common lymphatic markers include CCL21, MMR1, desmoplakin, and integrin α9 ([@B69]), all of which are also expressed by other liver resident cells and thus distinguishing liver lymphatics, especially in mouse models, has been difficult. [Table 1](#T1){ref-type="table"} outlines common markers and overlap among other liver specific cell populations in mice. Combinations of these markers can be used for the identification of LEC in the liver by flow cytometry and immunofluorescence as described in [@B29].

###### 

Marker distribution that can be used to distinguish lymphatic endothelial cells (LEC) ([@B42]; [@B29]; [@B81]) from hepatocytes ([@B23]; [@B33]), cholangiocytes ([@B32]; [@B48]; [@B51], [@B52]), liver sinusoidal endothelial cells (LSEC) ([@B77]; [@B20]; [@B80]), and portal endothelial cells (PEC) ([@B77]) for flow cytometry or immunofluorescence.

                **Hepatocytes**   **Cholangiocytes**   **LSEC**   **PEC**   **LEC**
  ------------- ----------------- -------------------- ---------- --------- ---------
  PDPN          −                 \+                   −          −         \+
  Prox1         \+                −                    −          −         \+
  LYVE-1        −                 −                    \+         −         \+
  Vegfr3/Flt4   −                 \+                   \+         \+        \+
  CK19          −                 \+                   −          −         −
  Albumin       \+                −                    −          −         −
  CCL21         −                 −                    ±          −         \+
  CD146         −                 −                    \+         \+        −/low

To address this, our recent studies evaluated liver LECs by single cell mRNA sequencing. However, we were unable to uncover a marker that is specific to LECs in the liver ([@B81]). We were able to differentiate LECs from other cells in the liver through the combined expression of *PDPN*, *LYVE1*, *PROX1*, VEGFR3 (*FLT4*), and *CCL21*. While the expression of these markers individually are not unique to the LECs in the liver, LECs are the only population of cells that express all of these markers together. Using these cell markers, we identified that the LECs within a cirrhotic liver are actively proliferating, consistent with increased lymphatic vessel density ([@B81]). We also discovered that LECs in disease upregulate pathways involved in the production of superoxide and reactive oxygen species consistent with the LECs responding to liver inflammation ([@B81]).

The transcriptional profile of LECs in the liver is dependent on disease etiology. Specifically, during chronic HCV infection the LECs upregulate genes associated with responses to increased interferon in the liver through Signal Transducer and Activator of Transcription 1 (STAT1), among others. In contrast, LECs isolated from the livers of patients with obesity associated NASH, upregulated genetic programs related to downstream cholesterol signaling and IL13 signaling, potentially through the upregulation of CD36 and p38 mitogen activated protein kinase (MAPK) ([@B81]). This study was the first to report the transcriptional profile of LECs isolated from healthy or cirrhotic human livers. Whether these transcriptional differences cause lymphatic dysfunction can only be inferred based on responses in other tissues.

Obesity and Lymphatics {#S5}
======================

In recent years obesity has been implicated as the cause of many diseases including cardiovascular disease, diabetes, and NASH. As excess stress on the body caused by obesity results in a type of chronic inflammatory state in the liver, heart and other organs it is perhaps not surprising that the lymphatic system is also affected. In an elegant report, [@B31] demonstrated that obesity is a root cause of lymphatic dysfunction in the skin. Additionally, recent reports suggest that peri-lymphatic inflammation results in lymphatic structures that are functionally impaired causing defective interstitial fluid drainage and decreased dendritic cell (DC) migration ([@B89]). Lymphatic dysfunction together with inflammation caused by disease can worsen inflammation and disease pathology ([@B18]). In these studies, it was demonstrated that stearic acid, a long chain fatty acid commonly associated with obese tissues was highly toxic to LECs *in vitro*. This toxicity could be prevented by increasing phosphatidylinositol-triphosphate (PIP3) kinase signaling ([@B71]; [@B37]; [@B84]), presumably through phosphatase and tensin homolog (PTEN) activity ([@B31]). PTEN can be activated by VEGFR3 tyrosine kinase receptor activity ([@B31]). Furthermore, the peri-lymphatic inflammation seen was described to be a result of CD4^+^ T cell and/or macrophage activity as lymphatic defects were ameliorated in CD4^+^ T cell depleted mice fed a high fat diet ([@B86]); and macrophage crown like structures were observed in close proximity to defective LV ([@B31]). Intriguingly, lymphatic dysfunction, inflammation and iNOS activity can all be reversed by weight loss ([@B60]). This is perhaps not too surprising as many of the co-morbidities associated with obesity are also resolved after weight loss ([@B53]). Finally, in *Prox1* heterozygous mice, a genetic model of lymphatic dysfunction ([@B91]; [@B39]; [@B74]), the LV become ruptured and "leaky" ([@B27]). The ruptured and leaky lymphatics to lead to the accumulation of free fatty acids in the surrounding adipose tissue and increased adipogenesis ([@B39]; [@B28]). These findings suggest that obesity not only drives lymphatic dysfunction, but that lymphatic dysfunction can drive obesity. Thus, in the setting of obesity associated liver disease it is possible that increased steatosis and the resulting inflammation, steatohepatitis, may occur around LC or vessels. This peri-lymphatic inflammation could cause toxicity or changes in signaling pathways in LECs that lead to decreased lymphatic integrity and increased adipogenesis in the surrounding tissues.

VEGF and Chylomicron Transport {#S6}
==============================

The lymphatics within the intestinal villi, lacteals, are required for dietary fat uptake. The lacteals have highly permeable "button-like" junctions that allow for the acquisition of dietary fat, in the form of chylomicrons. As such, genetic deletion of *Neuropillin 1* together with *Vascular endothelial growth factor receptor 1* in endothelial cells, resulted in a decrease of button-like junctions and increase in zipper-like junctions in intestinal lacteals that led to the malabsorption of chylomicrons ([@B100]). Additionally, complete loss of VEGFC expression by LECs in adult mice led to severe defects in lacteal regeneration and compromised dietary fat absorption ([@B61]). VEGFD (a VEGFR3 ligand) has also been shown to participate in the removal of chylomicron remnants from the blood ([@B85]). In a recent report, [@B85] found that loss of VEGFD resulted in the downregulation of syndecan 1 (SDC1) on the sinusoidal surface of hepatocytes ([@B85]). SDC1 is a receptor for APO-B found in chylomicron remnants. APO-B is also important for hepatic uptake of tri-glyceride rich lipoproteins. These new findings demonstrate that VEGFD can mediate crosstalk between the LSECs and hepatocytes for chylomicron remnant removal from the blood. However, what contribution loss of VEGFD had to liver lymphangiogenesis or reverse cholesterol transport was not investigated. This work suggests an intimate crosstalk between the vascular and lymphatic endothelium with liver and intestine specific cells. This crosstalk appears to have both specific and non-specific consequences for lipid and cholesterol metabolism, lymphatic growth and differentiation, and/or transport of fatty acids and chylomicrons throughout the body.

Hypercholesterolemia and Lymphatics {#S7}
===================================

In addition to the interplay between obesity and lymphatics, recent studies have highlighted the role of lymphatics in reverse cholesterol transport and the impact of hypercholesterolemia on lymphatic function. Reverse cholesterol transport is the process of the removal of cholesterol from peripheral tissues back to the liver where it is excreted through the bile ([@B12]). This process requires cholesterol to be received by the lymphatic vasculature before entering into the blood stream at the thoracic duct ([@B41]). Recent reports have suggested that LV are not just passive transporters of cholesterol, but instead may be actively involved in the regulation of fatty acids and cholesterol transport from the tissue similar to how lymphatics regulate immune cell transport ([@B6]; [@B70]; [@B50]; [@B55]). In light of this, several studies have recently been done to understand the impact of cholesterol on lymphatic function. Many of these studies have been performed in *ApoE*−/− mice fed a high fat diet. These mice have exceptionally high levels of cholesterol and LV are more tortuous, dilated, and have areas of smooth muscle cell coverage that are irregular ([@B49]). As a result, using lymphocyntigraphy and DC migration assays, these LV were functionally impaired in their ability to transport fluid from the tissue or DCs to the LN and this could be rescued by treatment with a cholesterol reducing agent, ezetimibe ([@B50]). Hypercholesterolemia also led to increased levels of cholesterol in the tissues and LNs which could be rescued by VEGFC or VEGFD treatment ([@B50]). Further, loss of the cholesterol receptor SR-BI completely ablated cholesterol transport through the lymph ([@B50]). Finally, it was shown that hypercholesterolemia increased LN cellularity by disrupting normal lymphatic structures ([@B83]). This was due to decreased S1P secretion into the lymph, decreased *Sphk1* transcript (which catalyzes the biosynthesis of SIP) by LECs and increased *Spgl1* transcript which degrades S1P thereby decreasing lymphocyte egress from the LN ([@B83]). The effect of cholesterol on LV has yet to be fully understood, but could have a major impact on lymphatic function across systems resulting in defects in lymphocyte trafficking, cholesterol or triglyceride accumulation in the tissue, chylomicron uptake or chylomicron remnant removal. Cholesterol and oxidized cholesterol species are increased in the livers of patients with CLD, thus understanding the impact of cholesterol on lymphatics is essential for understanding lymphatic function in the liver during disease.

To gain insight into specialized roles for liver LECs during disease our recent report examined how LECs respond to cholesterol species retained in the liver during disease, such as highly oxidized low density lipoprotein (OX-LDL). While OX-LDL is a key player in the pathogenesis of atherosclerosis ([@B19]; [@B30]), it has only recently been appreciated that OX-LDL can contribute to the progression of liver disease. OX-LDL accumulates as a result of free radicals generated by inflammation and can directly induce liver injury ([@B101]). Further, levels of OX-LDL are elevated in patients with NASH ([@B2]), HCV ([@B59]), ALD ([@B1]; [@B78]), and cholestasis ([@B16]; [@B43]). This increased OX-LDL in the pathogenesis of CLD is consistent with our transcriptional data from LECs from livers of people with NASH, in that pathways involved in free radical scavenging, IL13 signaling and genes involved in cholesterol sensing were upregulated ([@B81]). In our studies, OX-LDL induced the production IL13 by LECs in livers of mice but not LN LECs and in contrast to the interferon inducing toll-like receptor (TLR) agonist, polyI:C ([@B81]). LECs have been shown to produce, IL-1β, IL-6, IL-7, IL-8, and iNOS during inflammation and TGFβ at baseline ([@B13]), however, IL-13 production by LECs had yet to be reported. These findings were interesting as recent evidence demonstrated that IL4 and IL13 can reduce *Prox1* expression ([@B75]; [@B79]). In addition to the expression of IL13, LECs are one of the few cell types to express both IL13Rα1 and IL13Rα2, suggesting that LECs have the ability to both produce and respond to IL13 ([@B40]). When OX-LDL was administered to human LECs *in vitro*, *Prox1* and *Vegfr3* expression were decreased ([@B81]), similar to what was seen when LECs were treated with recombinant IL13 ([@B75]; [@B79]). This loss of *Prox1* could significantly affect lymphatic differentiation as in an elegant paper by [@B96], it was demonstrated that LECs upregulate fatty acid oxidation (FAO) in a positive feedback loop that that requires PROX1, p300 and CPT1a to promote lymphatic growth and lymphatic specific chromatin modifications. These findings are important as we begin to investigate how OX-LDL and/or IL13 could manipulate the function of LEC and also how the metabolic state of the LEC can be the consequence and/or cause of chronic disease states. This is especially intriguing in the liver as blocking IL-13 can reduce liver fibrosis-at least in a Schistosoma infection model ([@B15]). Thus, understanding how different inflammatory mediators within the liver affect lymphatic function will be important for developing novel and specific therapeutic targets for liver lymphatics.

Bypass of First Pass Metabolism in the Liver by Targeting Lymphatics {#S8}
====================================================================

Another recent and intriguing area of research regarding lymphatics and the liver is currently being explored within the pharmacologic community. First pass metabolism is a process in which oral drug administration results in drug metabolism in the liver. When the drug passes directly from the intestine into the hepatic PV it is rapidly cleared in the liver via drug metabolizing enzymes, transporters and secretion through the bile ([@B3]; [@B4]; [@B54]; [@B57]). This rapid clearance of drugs decreases therapeutic efficacy of the orally administered drug. To circumvent these issues, the lymphatic system is being targeted to bypass first pass metabolism by the liver. As stated above, the lacteals are required for dietary fat uptake from enterocytes in the form of chylomicrons. Through microemulsion formulations of lipids ([@B45]), self-microemulsifying drug delivery systems (SMEDDS) ([@B47]), chemical modification with fatty acyl groups/esterification ([@B11], [@B10]) and other lipid formulations ([@B35]), several groups have targeted the lacteals for oral drug uptake. Targeting lymphatic uptake in the gut results in both localized and systemic drug delivery by bypassing the liver. This method for drug delivery has many potential uses, of which a particularly intriguing area of research is to improve delivery of drugs that modulate immune function. To this end, delivery of lipophilic alkyl derivatives or triglyceride derivatives of the immunosuppressive drug mycophenolic acid (MPA) caused MPA to enter into the lymphatic system, pass into the mesentery and ultimately into the mesenteric LNs to the targeted immune cells ([@B36]). These studies demonstrate a novel way for specifically reaching the lymphatic and the immune system with lipophilic drugs. This is important as we negotiate new ways to manipulate lymphatic or immune function in different organ systems.

Conclusion and Future Goals {#S9}
===========================

As we move forward into understanding differences in LECs based on their tissue microenvironment we are likely to come across novel and specific pathways that could be targeted for disease therapeutics. Of particular interest are atherosclerosis, inflammatory bowel disease, or CLD in which LC and vessels are important for the clearance of inflammatory infiltrate, protein, cholesterol and triglycerides from the tissue. VEGF-C and VEGF-D have pleiotropic effects, but could be developed for use as recombinant proteins, agonistic antibodies or small molecules to potentiate lymphatic growth and/or function across the board to improve organ health. Similarly, the mTOR inhibitor, sirolimus, has been shown to limit downstream VEGFR3 signaling thereby aiding in diseases where lymphatic malformations occur ([@B7]; [@B67]; [@B64],[@B65],[@B66]). Presumably, based on preclinical models of myocardial infarction promoting lymphangiogenesis could improve organ function ([@B46]). However, based on recent findings it may be more relevant to focus our studies on understanding the specific contributors to lymphatic dysfunction, such as OX-LDL, and target the removal of those inflammatory mediators instead. In parallel, it will be important to understand downstream signaling pathways in LECs caused by inflammatory mediators or inflammatory cells with the end goal of maintaining lymphatic function through the prevention of signals induced by the inflammation. In the end, it is important for us to understand differences in lymphatics in each organ system, the specific stressors these cells encounter and how they can be targeted using lipophilic drug derivatives. At this time it is fairly evident that a common function of lymphatics across systems is to promote lipid and protein homeostasis to maintain organ health.
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